NEW YORK (Reuters) – A U.S. judge on Wednesday dismissed a lawsuit accusing Bristol Myers Squibb Co of defrauding investors who stood to receive $6.4 billion had it won federal approval by specified deadlines for drugs developed by the former Celgene Corp.
(Reporting by Jonathan Stempel in New York; Editing by Leslie Adler)
